Alx Oncology Holdings (ALXO) Other financing activities (2020 - 2026)
Alx Oncology Holdings recorded quarterly Other financing activities of $670000.0 in Q1 2026, up 66900.0% quarter-over-quarter from $1000.0 in Q3 2025.
Alx Oncology Holdings' Other financing activities history runs 7 years deep, the most recent figure standing at $670000.0 for Q1 2026.
- In Q1 2026, Other financing activities changed N/A year-over-year to $670000.0; the TTM figure through Mar 2026 stood at $670000.0 (changed N/A YoY), while the FY2025 annual figure was $14000.0, down 99.14% from the prior year.
- Other financing activities came in at $670000.0 for Q1 2026 at Alx Oncology Holdings, up from $1000.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $861000.0 in Q2 2024 to a low of -$1000.0 in Q2 2025.
- A 5-year average of $271000.0 and a median of $185000.0 in 2022 frame the typical range for Other financing activities.
- Across the five-year window, Other financing activities jumped 668.75% in 2024 and slumped 100.12% in 2025, its largest moves.
- Alx Oncology Holdings' Other financing activities stood at $222000.0 in 2022, then sank by 49.55% to $112000.0 in 2023, then surged by 376.79% to $534000.0 in 2024, then slumped by 99.81% to $1000.0 in 2025, then soared by 66900.0% to $670000.0 in 2026.
- According to Business Quant data, Other financing activities over the past three periods registered $670000.0, $1000.0, and -$1000.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Alx Oncology Holdings | 189.80 Mn | 49.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 670,000.00 |
| Mar 31, 2026 | 670,000.00 |
| Sep 30, 2025 | 1,000.00 |
| Sep 30, 2025 | 1,000.00 |
| Jun 30, 2025 | -1,000.00 |
| Jun 30, 2025 | -1,000.00 |
| Sep 30, 2024 | 534,000.00 |
| Sep 30, 2024 | 534,000.00 |
| Jun 30, 2024 | 861,000.00 |
| Jun 30, 2024 | 861,000.00 |
| Mar 31, 2024 | 237,000.00 |
| Mar 31, 2024 | 237,000.00 |
| Jun 30, 2023 | 112,000.00 |
| Jun 30, 2023 | 112,000.00 |
| Dec 31, 2022 | 222,000.00 |
| Dec 31, 2022 | 222,000.00 |
| Sep 30, 2022 | 5,000.00 |
| Sep 30, 2022 | 5,000.00 |
| Jun 30, 2022 | 155,000.00 |
| Jun 30, 2022 | 155,000.00 |
| Mar 31, 2022 | 185,000.00 |
| Mar 31, 2022 | 185,000.00 |
| Dec 31, 2021 | 530,000.00 |
| Dec 31, 2021 | 530,000.00 |
| Sep 30, 2021 | 533,000.00 |
| Sep 30, 2021 | 533,000.00 |
| Jun 30, 2021 | 464,000.00 |
| Jun 30, 2021 | 464,000.00 |
| Mar 31, 2021 | 1.02 Mn |
| Mar 31, 2021 | 1.02 Mn |
| Dec 31, 2020 | 12.50 Mn |
| Dec 31, 2020 | 12.50 Mn |
| Sep 30, 2020 | 299,000.00 |
| Sep 30, 2020 | 299,000.00 |